Pharmaceutical Technology's In the Lab eNewsletter, December 2022

Advances in contamination control are being to mitigate the presence of pollutants in drug products.

One can improve method precision and productivity by replacing one step in sample preparation with an automated approach.

Advancing digital transformation can significantly reduce R&D costs and shorten drug discovery timelines.

The $286 million investment ability is designed to elevate MillioporeSigma’s ability to conduct biosafety testing and analytical development services.

The Pioneer Antibody Discovery Platform is a new antibody discovery service specifically designed to develop best-in-class biologic candidates.

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

Element has opened a new 7500-ft3 facility that will be used to evaluate aerosolized product efficacy for reducing airborne organisms and viral particles.

The deal will see Sanofi use Insilico’s AI drug discovery platform to advance up to six new drug development candidates.

Salipro Biotech has entered into a collaboration and license agreement with Sanofi to advance discovery programs.

The latest guidance from FDA discusses recommendations on demonstrating sameness between the active ingredient in a proposed generic drug product and its reference listed drug.

The collaboration will see Shimadzu and UMG develop new clinical laboratory methods using LC-MS for TDM analysis.

Gerresheimer and Nelson Labs will work together to conduct extractables and leachables testing on upcoming primary packaging solutions.